Kyntra BioLTS:0IL8 52 Net Margin % is -406.58% as of Mar. 2026. GuruFocus rates LTS:0IL8 with a GF Score™ of 52/100 and a GF Value™ of $5.68 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 947 Biotechnology companies, Kyntra Bio ranks better than 99.47% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Kyntra Bio's Net Income for the
three
months ended in Mar. 2026 was $-15.20 Mil. Kyntra Bio's Revenue for the
three
months ended in Mar. 2026 was $3.74 Mil. Therefore, Kyntra Bio's net margin for the quarter that ended in Mar. 2026 was -406.58%.
The historical rank and industry rank for Kyntra Bio's Net Margin % or its related term are showing as below:
LTS:0IL8'
s Net Margin % Range Over the Past 10 Years
Min: -607.29 Med: -99.82 Max: 2848.63
Current: 2199.42
LTS:0IL8's Net Margin % is ranked better than 99.47% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs LTS:0IL8: 2199.42
Kyntra Bio (LTS:0IL8) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Kyntra Bio Net Margin % Related Terms
Kyntra Bio Net Margin % Historical Data
* Premium members only.
The historical data trend for Kyntra Bio's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0IL8 vs SER, SNSE, PVCT: Net Margin % Comparison
For the Biotechnology subindustry, Kyntra Bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyntra Bio Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kyntra Bio's Net Margin % distribution charts can be found below:
* The bar in red indicates where Kyntra Bio's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyntra Bio (LTS:0IL8) has a Net Margin % of -406.58% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Kyntra Bio and its competitors. According to the industry distribution chart, Kyntra Bio ranks #5 out of 947 companies in the Biotechnology industry, placing it in the top 0.5%.
Is Kyntra Bio's Net Margin % too high?
Kyntra Bio's current Net Margin % is -406.58%. Based on the distribution chart, Kyntra Bio ranks #5 out of 947 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kyntra Bio has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Net Margin % compare to SER and SNSE?
According to the Biotechnology industry distribution chart, Kyntra Bio ranks #5 out of 947 companies for Net Margin %. This places Kyntra Bio in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current Net Margin % is -406.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.68, compared to a current price of $6.86 — trading 20.7% above its estimated fair value. The current Net Margin % is -406.58%. Kyntra Bio's overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current Net Margin % is -406.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?
Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued.
The current stock price of $6.86 is trading 20.7% above its estimated GF Value™ of $5.68.
GuruFocus considers Kyntra Bio to be Modestly Overvalued.
Key valuation signals for LTS:0IL8:
Net Margin %: -406.58%
GF Value™: $5.68 vs. price of $6.86 (20.7% above fair value)
No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
52GF Score
Get the complete analysis for LTS:0IL8
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0IL8 has been successfully added to your 
